...
首页> 外文期刊>Current pharmaceutical design >Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs
【24h】

Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs

机译:DNA-抗癌药物相互作用的阐明方法及其在新药开发中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

DNA damaging agents including anthracyclines, camptothecins and platinum drugs are among most frequently used drugs in the chemotherapeutic routine. Due to their relatively low selectivity for cancer cells, administration of these drugs is associated with adverse side effects, inherent genotoxicity with risk of developing secondary cancers. Development of new drugs, which could be spared of these drawbacks and characterize by improved antitumor efficacy, remains challenging yet vitally important task. These properties are in large part dictated by the selectivity of interaction between the drug and DNA and in this way the studies aimed at elucidating the complex interactions between ligand and DNA represent a key step in the drug development. Studies of the drug-DNA interactions encompass determination of DNA sequence specificity and mode of DNA binding as well as kinetic, dynamic and structural parameters of binding. Here, we consider the types of interactions between small molecule ligands and polynucleotides, how they are affected by DNA sequence and structure, and what is their significance for the antitumor activity. Based on this knowledge, we discuss the wide array of experimental techniques available to researchers for studying drug-DNA interactions, which include absorption and emission spectroscopies, NMR, magnetic and optical tweezers or atomic force microscopy. We show, using the clinical and experimental anticancer drugs as examples, how these methods provide various types of information and at the same time complement each other to provide full picture of drugDNA interaction and aid in the development of new drugs.
机译:DNA破坏剂包括蒽环类,喜树碱和铂类药物是化疗常规中最常用的药物。由于它们对癌细胞的选择性相对较低,因此这些药物的给药与不良副作用,固有的遗传毒性以及发生继发性癌症的风险有关。可以克服这些缺点并以提高的抗肿瘤功效为特征的新药的开发仍然是具有挑战性但至关重要的任务。这些性质在很大程度上取决于药物与DNA之间相互作用的选择性,因此,旨在阐明配体与DNA之间复杂相互作用的研究代表了药物开发的关键步骤。药物与DNA相互作用的研究包括DNA序列特异性和DNA结合模式的测定,以及结合的动力学,动力学和结构参数。在这里,我们考虑了小分子配体与多核苷酸之间相互作用的类型,它们如何受到DNA序列和结构的影响,以及它们对抗肿瘤活性的意义。基于此知识,我们讨论了研究人员可用于研究药物与DNA相互作用的各种实验技术,包括吸收和发射光谱,NMR,磁和光镊或原子力显微镜。我们以临床和实验性抗癌药物为例,展示了这些方法如何提供各种类型的信息,同时又相辅相成,从而提供了药物DNA相互作用的全貌,并有助于开发新药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号